ross • January 4, 2024
ODYSSEY nHCM (aka Hypertrophic Cardiomyopathy without obstruction)

We are looking for HCM patients without obstruction experiencing shortness of breath,  palpitations, tiring easily, and want to be in a clinical trial. In this trial, HCM non-obstructed patients will have the opportunity to participate in a myosin inhibitor trial,  which assesses the safety and efficacy of mavacamten in this population. Mavacamten is an investigational product that has not been approved by FDA.  

The trial name is ODYSSEY. You might be eligible if you are age 18 or older and experience symptoms related to your HCM. If interested, please click the link to take this quick survey to see if you pre-qualify.  

In the survey, you can identify a clinical trial site and authorize HCMA to share your contact information with them, or you may contact them yourself.  

If you have additional questions, please email linda@4hcm.org or call the office at (973) 983-7429. 

HCMA Blog

Cytokinetics Logo of a green
By Erica Friedman May 14, 2025
Positive clinical trial endpoints for MAPLE-HCM study announced by Cyctokonetics for aficamten in obstructive hypertrophic cardiomyopathy
A Caucasian hand with a pen rests on a clipboard that holds paper with writing.
By Gordon Fox May 14, 2025
In the third of a series about decision-making and risk in HCM, Gordon Fox explains where risk data comes from and how to understand it.
4 diverse people stand under the mathmateical formula 25% = 1 in 4.
By Gordon Fox May 13, 2025
In part three of this series on decision making in HCM, Gordon Fox discusses how medical professionals define risk within a patient population, and what the different kinds of risk mean for a patient.
More Posts